FDA approval concerns a drug product, not simply the name of an ingredient. A compounded GLP-1 preparation does not acquire approval because a seller mentions an approved medicine or uses familiar ingredient terminology. Start by identifying exactly what is being prescribed, rather than treating two prices as interchangeable offers. [2]
Use The Virtual NP review and the PauseRx review to compare questions about prescribing, dispensing and payment. The selected prescription and purchase agreement matter more than the storefront name.
What approval tells you
For a new drug, FDA reviews testing and proposed labeling to decide whether the benefits outweigh the known risks for its intended use. Laboratory, animal and human testing contribute to that review. Approval is therefore meaningful evidence about the reviewed product and use; it is not a promise that treatment will suit every person. [1]
A compound is not an approved generic
An approved generic follows its own FDA approval process. The application must establish matters including the active ingredient, pharmaceutical equivalence, manufacturing consistency and how the drug reaches the bloodstream. FDA also reviews stability, packaging and labeling information. A familiar molecule name alone does not establish that a finished preparation meets those requirements. [3]
Ask whether the prescription is an FDA-approved finished product or an unapproved compound. Do not replace that distinction with a broad “same medicine” assurance. FDA specifically identifies semaglutide sodium and semaglutide acetate as different active ingredients from those used in approved drugs. [2]
503A and 503B describe different pathways
Section 503A provides exemptions from specified federal requirements when its conditions are met, including valid patient-specific prescriptions. Those exemptions include premarket approval and current good manufacturing practice requirements. Section 503B created outsourcing facilities, which remain subject to current good manufacturing practice requirements and FDA inspections on a risk-based schedule. They may supply patient-specific prescriptions or orders for office stock. [4]
These categories do not turn a compounded preparation into an approved product. Nor does nonapproval mean that no oversight exists. Ask which facility prepares the medicine and which framework it operates under; a platform name or a manufacturing badge does not answer both questions. [4]
Patient need and copy restrictions still matter
FDA recommends compounded GLP-1 drugs only for patients whose medical needs cannot be met by an approved drug. Discuss that need with the prescriber rather than assuming that a cheaper offer establishes suitability. [2]
In its April 1, 2026 policy update, FDA describes restrictions on essentially copying commercially available products under section 503A. It discusses a prescriber’s documented determination that a change produces a significant difference for an identified patient. It also describes separate restrictions on bulk drug substances used by outsourcing facilities under section 503B. [5]
The update includes dated enforcement policies and earlier historical sections. It does not provide a blanket permission slip for every compounded prescription, or a basis for declaring every offer illegal. Ask the prescriber and pharmacy how the selected preparation meets the applicable conditions. This guide does not determine an individual prescription’s legal eligibility or today’s drug availability. [5]
Make the label and measuring instructions clear
FDA’s dosing alert describes dosing errors involving compounded injectable semaglutide, including confusion when converting between milligrams, milliliters and syringe units. It notes varying concentrations. Before using a prescription, ask the clinician or pharmacist to explain the intended dose, concentration and matching syringe markings. Do not calculate a conversion from a seller’s generic webpage or another patient’s instructions. [6]
Request clarification when the vial, supplied equipment or directions differ from what you expected. Keep the prescription-specific written instructions together with the medicine information. Do not assume the container or instructions for another medicine apply to yours. [6]
Compare the actual prescription and bill
Use a written checklist: ingredient and preparation; route; concentration; quantity supplied; intended supply period; dispensing facility; and who answers medication questions. Separately request the total due, renewal date, care fees, laboratory charges, shipping and cancellation or refund conditions. These are purchase questions, not evidence that one provider’s preparation matches another’s.
A lower number does not establish the cause of a price difference, the quality of a particular batch or whether the offer meets your medical needs. Match the product and payment terms before comparing costs. If those details are unresolved, keep the quote separate rather than turning a starting amount into a complete monthly invoice.